Replies to post #189474 on NorthWest Biotherapeutics Inc (NWBO)

[Ultraz2]

Many can’t make that mistake twice, I know I can’t risk it...the studies have been very encouraging as many hard workers have been kind enough to calculate and walk many of us non-statistical brains through the process...it would be a great ending to my career as a nurse where I was blessed to have the opportunity to work in pediatric trauma and neurosurgery with Dr. Ben Carson at Hopkins. I knew there was a reason I loved neurosurgical nursing. GLTA

[flipper44]

1. On August 16, 2018, Michael Bigger met Dr. Liau.



2. On August 26, 2018, he tweeted the following.



3. Cavalli, the paid....um tweeter for NWBO....tweeted a response on the same day:

"We are all anxious but the longer the time for unblinding is expect to increase odds for success. Patience is key still."

(Apparently Cavalli can't be bothered with tense or editing tweets to billion dollar investors.)

Logic dictates just like Dr. Ashkan, Dr. Liau must think it's time to get this to patients. Seems more like patients not patience are key now Mr. Cavalli.

To me this strange "homerun" behavior by LP, MB and Cavalli (company) apparently versus the (clinicians) LL & KM, alerts my spidey senses there is a third party calling the shots -- a buyer who cares more about a higher price per patient than anyone above would. LP's strange denial of 250,000 pounds per year was, to me, a clear indication that logic dictates the price target is 250K total (not per year) -- which is still very expensive. (Larry Smith has used the 250K total price target in at least one fairly recent article.)

For her part, in an interview on a patient blog, Dr. Liau made it clear she realized the importance of long trials, but at the same time, when separately, in the same interview, discussing the L trial completion, stated it was in the company's hands now.

It is seeming more and more like any potential wait beyond the current NICE timeline is eventually framed to stick patients with a higher price tag at this point.

Unblind the data.

Just my opinion.